A recent University College London research estimates that 1.6 million adults in England, Wales and Scotland used GLP-1s, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight.
Fungi (Basel) 6, 28
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
ButlerAE , Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC
References Abawi, G
Wholesale Energy & Active Lifestyle Keep a pep in your step and fuel your fitness goals Reg